MCID: TRD006
MIFTS: 59

Tardive Dyskinesia

Categories: Rare diseases, Oral diseases, Neuronal diseases

Aliases & Classifications for Tardive Dyskinesia

MalaCards integrated aliases for Tardive Dyskinesia:

Name: Tardive Dyskinesia 53 72 49 50 28 69
Neuroleptic-Induced Tardive Dyskinesia 69
Lingual-Facial-Buccal Dyskinesia 69
Drug-Induced Tardive Dyskinesia 69
Linguofacial Dyskinesia 49
Tardive Oral Dyskinesia 49
Tardive Dystonia 49
Td 49

Characteristics:

OMIM:

53
Inheritance:
autosomal recessive predisposition


HPO:

31
tardive dyskinesia:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 53 272620
MedGen 39 C0686347
SNOMED-CT via HPO 65 258211005 88425004

Summaries for Tardive Dyskinesia

NIH Rare Diseases : 49 Tardive dyskinesia is a neurological movement disorder that is caused by the long-term use of a certain type of medications called neuroleptics. Neuroleptic drugs are usually prescribed for psychiatric conditions, although they may be used to treat gastrointestinal or neurological conditions in some cases. Tardive dyskinesia is primarily characterized by repetitive involuntary movements of the jaw, lips and tongue such as grimacing; sticking out the tongue; and smacking, puckering and pursing the lips. Some affected people may also experience involuntary rapid, jerking movements (chorea) or slow, writhing movements (athetosis) of the arms and/or legs. It is unclear why some people who take neuroleptic medications develop these symptoms while others do not. Treatment for this condition varies but may include stopping or minimizing the use of neuroleptic drugs and/or taking additional medications to to reduce the severity of the symptoms. Last updated: 12/18/2014

MalaCards based summary : Tardive Dyskinesia, also known as neuroleptic-induced tardive dyskinesia, is related to mood disorder and megacolon, and has symptoms including abnormality of the nervous system, myoclonus and spasmodic torticollis. An important gene associated with Tardive Dyskinesia is NQO1 (NAD(P)H Quinone Dehydrogenase 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Monoamine GPCRs. The drugs Aripiprazole and Chlorpromazine have been mentioned in the context of this disorder. Affiliated tissues include tongue, brain and eye, and related phenotypes are behavior/neurological and cardiovascular system

OMIM : 53 Tardive dyskinesia is a debilitating motor disorder manifest as hyperkinetic, involuntary, repetitive movements predominantly of the orofacial region. It is a complication of treatment with so-called typical antipsychotic or neuroleptic agents, such as chlorpromazine or haloperidol, and is estimated to occur in 20 to 30% of chronic schizophrenics on long-term treatment (Thelma et al., 2008). (272620)

NINDS : 50 Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may be present.

Wikipedia : 72 Tardive dyskinesia (TD) is a disorder that results in involuntary, repetitive body movements. This may... more...

Related Diseases for Tardive Dyskinesia

Diseases related to Tardive Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 mood disorder 29.7 COMT DRD2 HTR2A
2 megacolon 29.5 DRD2 HTR2A
3 bipolar i disorder 29.4 COMT HTR2A
4 schizophrenia 29.2 COMT CYP1A2 CYP2D6 DRD2 DRD3 HTR2A
5 schizoaffective disorder 29.1 COMT DRD2 DRD3 HTR2A
6 bipolar disorder 29.0 COMT DRD2 DRD3 HTR2A
7 major depressive disorder 28.9 COMT CYP2D6 DRD2 DRD3 HTR2A
8 drug induced dyskinesia 11.5
9 dystonia 10.5
10 delusional disorder 10.3 DRD2 DRD3
11 impulse control disorder 10.3 DRD2 DRD3
12 galactorrhea 10.3 CYP2D6 DRD2
13 episodic pain syndrome, familial, 1 10.2
14 migraine without aura 10.2 DRD2 DRD3
15 opiate dependence 10.2 DRD2 DRD3
16 neuroleptic malignant syndrome 10.2 CYP2D6 DRD2
17 schizophreniform disorder 10.2 COMT DRD2
18 oppositional defiant disorder 10.2 COMT DRD2
19 alexithymia 10.2 COMT DRD2
20 opioid addiction 10.1 COMT DRD2
21 neuronitis 10.1
22 traumatic brain injury 10.1 COMT DRD2
23 antisocial personality disorder 10.1 COMT DRD2
24 gastroparesis 10.1 CYP2D6 DRD2
25 amelogenesis imperfecta, type ib 10.1 CYP1A2 CYP2D6
26 cocaine dependence 10.1 DRD2 DRD3
27 female stress incontinence 10.1 CYP1A2 CYP2D6
28 toxicity or absent response to clozapine 10.1 COMT CYP1A2
29 brain injury 10.1 COMT DRD2
30 alzheimer disease 10.0
31 gilles de la tourette syndrome 10.0
32 popliteal pterygium syndrome, lethal type 10.0
33 aging 10.0
34 alacrima, achalasia, and mental retardation syndrome 10.0
35 dementia 10.0
36 hypothyroidism 10.0
37 substance dependence 10.0 CYP2D6 DRD2 DRD3
38 polysubstance abuse 10.0 COMT DRD2 DRD3
39 alcoholic psychosis 10.0 DRD2 HTR2A
40 restless legs syndrome 9.9 COMT DRD2 DRD3
41 periodic limb movement disorder 9.9 DRD2 HTR2A
42 bruxism 9.9 DRD2 HTR2A
43 tic disorder 9.9 DRD2 HTR2A
44 drug-induced mental disorder 9.9 DRD2 HTR2A
45 drug psychosis 9.9 DRD2 HTR2A
46 major affective disorder 1 9.9
47 multiple sclerosis 9.9
48 dementia, lewy body 9.9
49 huntington disease 9.9
50 choreoacanthocytosis 9.9

Comorbidity relations with Tardive Dyskinesia via Phenotypic Disease Network (PDN): (show all 16)


Acute Cystitis Alzheimer Disease
Anxiety Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophagitis
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Paranoid Schizophrenia
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Tardive Dyskinesia:



Diseases related to Tardive Dyskinesia

Symptoms & Phenotypes for Tardive Dyskinesia

Symptoms via clinical synopsis from OMIM:

53
Neuro:
tardive dyskinesia
repetitive rapid body movements
chewing movements
oral-lingual-buccal dyskinesia
tongue darting
more
Misc:
complication of treatment with neuroleptic agents


Clinical features from OMIM:

272620

Human phenotypes related to Tardive Dyskinesia:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 31 HP:0000707
2 tardive dyskinesia 31 HP:0040141

UMLS symptoms related to Tardive Dyskinesia:


myoclonus, spasmodic torticollis

MGI Mouse Phenotypes related to Tardive Dyskinesia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 COMT CYP1A2 DRD2 DRD3 HSPG2 HTR2A
2 cardiovascular system MP:0005385 9.43 COMT CYP1A2 DRD2 DRD3 HSPG2 SOD2
3 liver/biliary system MP:0005370 9.02 CYP1A2 DRD2 HSPG2 NQO1 SOD2

Drugs & Therapeutics for Tardive Dyskinesia

Drugs for Tardive Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
3
Dopamine Approved Phase 4,Phase 3,Phase 1 51-61-6, 62-31-7 681
4
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1 132539-06-1 4585
5
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1 106266-06-2 5073
6
Zolpidem Approved Phase 4 82626-48-0 5732
7 Zotepine Approved, Investigational Phase 4 26615-21-4
8
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
9
Galantamine Approved Phase 4 357-70-0 9651
10
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
11
Nicotine Approved Phase 4 54-11-5 89594 942
12
Ziprasidone Approved Phase 4 146939-27-7 60854
13 tannic acid Approved, Nutraceutical Phase 4
14 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
16 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
17 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antidepressive Agents Phase 4
19 Antiemetics Phase 4,Phase 1
20 Antimanic Agents Phase 4
21 Autonomic Agents Phase 4,Phase 1
22 Dopamine Agents Phase 4,Phase 3,Phase 1
23 Dopamine Antagonists Phase 4,Phase 3,Phase 1
24 Gastrointestinal Agents Phase 4,Phase 1
25 Lithium carbonate Phase 4 554-13-2
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
29
Serotonin Phase 4,Phase 3,Phase 1 50-67-9 5202
30 Serotonin Agents Phase 4,Phase 3,Phase 1
31 Serotonin Uptake Inhibitors Phase 4,Phase 1
32 GABA Agents Phase 4
33 GABA Agonists Phase 4
34 GABA-A Receptor Agonists Phase 4
35 Hypnotics and Sedatives Phase 4
36 Serotonin Antagonists Phase 4,Phase 3,Phase 1
37 sultopride Phase 4
38 Cholinergic Agents Phase 4,Phase 1,Phase 2
39 Cholinesterase Inhibitors Phase 4
40 Nootropic Agents Phase 4,Phase 3,Phase 2
41 Antidepressive Agents, Second-Generation Phase 4
42 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
43 Cytochrome P-450 Enzyme Inhibitors Phase 4
44 Dopamine Uptake Inhibitors Phase 4
45 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2
46
Tetrabenazine Approved, Investigational Phase 3,Phase 2 58-46-8 6018
47 Piracetam Approved, Investigational Phase 3,Phase 2 7491-74-9
48
Propranolol Approved, Investigational Phase 2, Phase 3 525-66-6 4946
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
50
Pyridoxal Approved, Nutraceutical Phase 3,Phase 2 66-72-8 1050

Interventional clinical trials:

(show top 50) (show all 52)

# Name Status NCT ID Phase Drugs
1 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
2 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
3 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Unknown status NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
4 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
5 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
6 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
7 Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine
8 Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
9 The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia Completed NCT00495352 Phase 4 Hihg-doseNRT, Low-dose NRT, bupropion
10 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4 ziprasidone
11 Addressing Involuntary Movements in Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
12 Aim to Reduce Movements in Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
13 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3 NBI-98854;Placebo
14 Piracetam for Treatment Tardive Dyskinesia Completed NCT00190008 Phase 3 piracetam
15 Extract of Ginkgo Biloba and Tardive Dyskinesia Completed NCT00672373 Phase 3 Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
16 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3 NBI-98854
17 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3 levetiracetam;placebo
18 Xenazine in Late Dyskinetic Syndrome With Neuroleptics Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
19 A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia Completed NCT00210769 Phase 3 paliperidone ER Oros
20 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
21 Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation Completed NCT00065286 Phase 3
22 Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Recruiting NCT03176771 Phase 2, Phase 3 MT-5199;Placebo
23 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Recruiting NCT03254186 Phase 2, Phase 3 Propranolol Hydrochloride;Placebo Oral Tablet
24 Reducing Involuntary Movements in Tardive Dyskinesia Active, not recruiting NCT02198794 Phase 3 SD-809;Placebo
25 D-Serine Treatment For Tardive Dyskinesia Active, not recruiting NCT01804920 Phase 2, Phase 3
26 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Enrolling by invitation NCT02736955 Phase 3 Valbenazine
27 Pyridoxal Kinase Activity in Tardive Dyskinesia Withdrawn NCT01908452 Phase 3 Pyridoxine
28 Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia Unknown status NCT00621634 Phase 2
29 Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia Unknown status NCT00331669 Phase 2
30 Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Completed NCT01267188 Phase 2 NBI-98854
31 A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia Completed NCT02064010 Phase 2 SNC-102;Placebo
32 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Completed NCT01733121 Phase 2 NBI-98854;NBI-98854;Placebo
33 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) Completed NCT01688037 Phase 2 NBI-98854;NBI-98854;Placebo
34 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT01393600 Phase 2 NBI-98854;NBI-98854;Placebo
35 Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia Completed NCT00175955 Phase 2 Levetiracetam
36 Dysport for the Treatment of OMD Completed NCT01921270 Phase 1, Phase 2 Low Dose - AbobotulinumtoxinA
37 Heart Rate Variability in Response to Metformin Challenge Completed NCT02500628 Phase 2 Metformin
38 Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia Completed NCT00401089 Phase 1, Phase 2 Panax Ginseng
39 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia Completed NCT01176721 Phase 2
40 Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia Terminated NCT00917293 Phase 2 Pyridoxal 5'-Phosphate;Placebo
41 Movement Disorders Caused by Antipsychotic Drugs in Older Patients Completed NCT00255879 Phase 1 Quetiapine;Risperidone;Olanzapine
42 Validation of the Implantation of a New Electrode for the Treatment of Dystonia Unknown status NCT02509338
43 Melatonin Treatment for Tardive Dyskinesia in Schizophrenia Completed NCT01391390 Melatonin;Placebo
44 The Assessment of Movement Disorders Utilizing Live Two-Way Video Completed NCT01467089
45 CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness Completed NCT01149551
46 Effect of Activity on Sleep of Cognitively-Impaired Veterans Completed NCT00013182
47 Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. Recruiting NCT02840760
48 Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia Recruiting NCT03287778
49 Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents Recruiting NCT03062033
50 ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders Recruiting NCT02252380

Search NIH Clinical Center for Tardive Dyskinesia

Genetic Tests for Tardive Dyskinesia

Genetic tests related to Tardive Dyskinesia:

# Genetic test Affiliating Genes
1 Tardive Dyskinesia 28

Anatomical Context for Tardive Dyskinesia

MalaCards organs/tissues related to Tardive Dyskinesia:

38
Tongue, Brain, Eye, Bone, Heart, Globus Pallidus, Cortex

Publications for Tardive Dyskinesia

Articles related to Tardive Dyskinesia:

(show top 50) (show all 642)
# Title Authors Year
1
Amisulpride Reexposure and Tardive Dyskinesia. ( 29403138 )
2018
2
Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies. ( 29427000 )
2018
3
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. ( 29338466 )
2018
4
Anticholinergic medication for antipsychotic-induced tardive dyskinesia. ( 29341071 )
2018
5
VMAT2 inhibitors for the treatment of tardive dyskinesia. ( 29433808 )
2018
6
Clinical risk factors for the development of tardive dyskinesia. ( 29439776 )
2018
7
Two New Drugs for Tardive Dyskinesia Hit the Market. ( 29369770 )
2018
8
Deuterium Tetrabenazine for Tardive Dyskinesia. ( 29341821 )
2018
9
Tardive dyskinesia: Epidemiology. ( 29433811 )
2018
10
Benzodiazepines for antipsychotic-induced tardive dyskinesia. ( 29352477 )
2018
11
The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate. ( 29338294 )
2018
12
Tardive dyskinesia: Out of the shadows. ( 29449008 )
2018
13
Future directions in tardive dyskinesia research. ( 29433809 )
2018
14
Vitamin E for antipsychotic-induced tardive dyskinesia. ( 29341067 )
2018
15
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. ( 29409162 )
2018
16
Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. ( 29433806 )
2018
17
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. ( 29342497 )
2018
18
Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. ( 28750568 )
2017
19
Assessing Patients for Tardive Dyskinesia. ( 29345876 )
2017
20
Tardive Dyskinesia ( 28846278 )
2017
21
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. ( 28668671 )
2017
22
Aripiprazole-induced Tardive Dyskinesia in 13 Years Old Girl Successfully Treated with Biperiden: A Case Report. ( 28783940 )
2017
23
Clozapine-induced Tardive Dyskinesia. ( 28852265 )
2017
24
Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. ( 28812541 )
2017
25
Epidemiology and Prevention of Tardive Dyskinesia. ( 29345874 )
2017
26
Dramatic improvement of tardive dyskinesia movements by inline skating. ( 28696930 )
2017
27
Comparing Treatments for Tardive Dyskinesia. ( 29345877 )
2017
28
Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis. ( 28904507 )
2017
29
Pharmacological treatment of tardive dyskinesia: recent developments. ( 28727483 )
2017
30
Scopolamine alleviates involuntary lingual movements: tardive dyskinesia or dystonia? ( 28919765 )
2017
31
Tardive dyskinesia: motor system impairments, cognition and everyday functioning. ( 28877766 )
2017
32
Valbenazine for the treatment of tardive dyskinesia. ( 28699794 )
2017
33
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. ( 28839340 )
2017
34
A new class of VMAT-2 inhibitors for tardive dyskinesia. ( 28668670 )
2017
35
Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report. ( 28072646 )
2017
36
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. ( 28839341 )
2017
37
Valbenazine (Ingrezza) for tardive dyskinesia. ( 28520698 )
2017
38
Medication-Induced Tardive Dyskinesia: A Review and Update. ( 28638290 )
2017
39
Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. ( 28790021 )
2017
40
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. ( 28839342 )
2017
41
Successful Management of Tardive Dyskinesia with Quetiapine and Clonazepam in a Patient of Schizophrenia with Type 2 Diabetes Mellitus. ( 27121435 )
2016
42
Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials. ( 26979525 )
2016
43
Pharmacogenetics of tardive dyskinesia: an updated review of the literature. ( 27469238 )
2016
44
Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats. ( 27592482 )
2016
45
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data. ( 27138080 )
2016
46
Laughter therapy in a geriatric patient with treatment-resistant depression and comorbid tardive dyskinesia. ( 27164922 )
2016
47
Paliperidone Palmitate-Associated Severe Refractory Tardive Dyskinesia With Tardive Dystonia: Management and Six-Months Follow-Up. ( 27269958 )
2016
48
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies. ( 26813487 )
2016
49
Markedly Reduced Thermal Pain Perception in a Schizoaffective Patient with Tardive Dyskinesia. ( 27144045 )
2016
50
Propranolol therapy for Tardive dyskinesia: A retrospective examination. ( 27622970 )
2016

Variations for Tardive Dyskinesia

Expression for Tardive Dyskinesia

Search GEO for disease gene expression data for Tardive Dyskinesia.

Pathways for Tardive Dyskinesia

Pathways related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1 12.11 CYP1A2 CYP2D6 NQO1 SOD2
2
Show member pathways
11.6 DRD2 DRD3 HTR2A
3
Show member pathways
11.33 CYP1A2 CYP2D6 NQO1
4
Show member pathways
11.26 COMT CYP1A2
5
Show member pathways
11.23 COMT CYP1A2 CYP2D6
6 11.19 CYP1A2 NQO1
7 11.18 CYP1A2 NQO1
8 11.05 CYP1A2 CYP2D6
9 10.95 NQO1 SOD2
10 10.78 DRD2 DRD3
11
Show member pathways
10.67 COMT CYP1A2 CYP2D6 NQO1
12
Show member pathways
10.66 COMT CYP1A2 NQO1
13 10.55 COMT NQO1

GO Terms for Tardive Dyskinesia

Cellular components related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle GO:0030139 9.16 DRD2 DRD3
2 axon GO:0030424 9.13 COMT DRD2 HTR2A
3 dendrite GO:0030425 8.92 COMT DRD2 HTR2A NQO1

Biological processes related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.85 COMT CYP1A2 SOD2
2 aging GO:0007568 9.83 HTR2A NQO1 SOD2
3 response to organic cyclic compound GO:0014070 9.8 COMT CYP1A2 NQO1
4 response to ethanol GO:0045471 9.77 DRD2 DRD3 NQO1
5 locomotory behavior GO:0007626 9.73 DRD2 DRD3 SOD2
6 xenobiotic metabolic process GO:0006805 9.72 CYP1A2 CYP2D6 NQO1
7 negative regulation of protein kinase B signaling GO:0051898 9.71 DRD2 DRD3
8 circadian regulation of gene expression GO:0032922 9.7 DRD2 DRD3
9 visual learning GO:0008542 9.7 DRD2 DRD3
10 release of sequestered calcium ion into cytosol GO:0051209 9.7 DRD2 HTR2A
11 response to cocaine GO:0042220 9.69 DRD2 DRD3
12 positive regulation of cytokinesis GO:0032467 9.69 DRD2 DRD3
13 negative regulation of adenylate cyclase activity GO:0007194 9.69 DRD2 DRD3
14 negative regulation of blood pressure GO:0045776 9.68 DRD2 DRD3
15 response to morphine GO:0043278 9.68 DRD2 DRD3
16 response to axon injury GO:0048678 9.68 DRD2 SOD2
17 response to electrical stimulus GO:0051602 9.68 NQO1 SOD2
18 response to amphetamine GO:0001975 9.67 DRD2 DRD3
19 arachidonic acid secretion GO:0050482 9.67 DRD2 DRD3
20 drug metabolic process GO:0017144 9.66 CYP1A2 CYP2D6
21 response to immobilization stress GO:0035902 9.66 CYP1A2 SOD2
22 superoxide metabolic process GO:0006801 9.65 NQO1 SOD2
23 temperature homeostasis GO:0001659 9.65 DRD2 HTR2A
24 dopamine receptor signaling pathway GO:0007212 9.64 DRD2 DRD3
25 synaptic transmission, dopaminergic GO:0001963 9.64 DRD2 DRD3
26 negative regulation of protein secretion GO:0050709 9.63 DRD2 DRD3
27 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.63 DRD2 HTR2A
28 removal of superoxide radicals GO:0019430 9.62 NQO1 SOD2
29 prepulse inhibition GO:0060134 9.61 DRD2 DRD3
30 positive regulation of renal sodium excretion GO:0035815 9.61 DRD2 DRD3
31 G-protein coupled receptor internalization GO:0002031 9.59 DRD2 DRD3
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD3
33 hydrogen peroxide biosynthetic process GO:0050665 9.58 CYP1A2 SOD2
34 oxidative demethylation GO:0070989 9.57 CYP1A2 CYP2D6
35 regulation of cAMP metabolic process GO:0030814 9.54 DRD2 DRD3
36 heterocycle metabolic process GO:0046483 9.52 CYP1A2 CYP2D6
37 drug catabolic process GO:0042737 9.51 CYP1A2 CYP2D6
38 monoterpenoid metabolic process GO:0016098 9.49 CYP1A2 CYP2D6
39 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.48 DRD2 DRD3
40 negative regulation of dopamine receptor signaling pathway GO:0060160 9.46 DRD2 DRD3
41 acid secretion GO:0046717 9.43 DRD2 DRD3
42 regulation of dopamine secretion GO:0014059 9.43 DRD2 DRD3 HTR2A
43 response to histamine GO:0034776 9.4 DRD2 DRD3
44 alkaloid metabolic process GO:0009820 9.37 CYP1A2 CYP2D6
45 behavioral response to cocaine GO:0048148 9.33 DRD2 DRD3 HTR2A
46 regulation of locomotion involved in locomotory behavior GO:0090325 9.32 DRD2 DRD3
47 dopamine metabolic process GO:0042417 9.13 COMT DRD2 DRD3
48 response to drug GO:0042493 9.1 COMT CYP1A2 DRD2 DRD3 HTR2A SOD2
49 oxidation-reduction process GO:0055114 10 CYP1A2 CYP2D6 NQO1 SOD2

Molecular functions related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.76 CYP1A2 CYP2D6 NQO1 SOD2
2 monooxygenase activity GO:0004497 9.48 CYP1A2 CYP2D6
3 aromatase activity GO:0070330 9.43 CYP1A2 CYP2D6
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.4 CYP1A2 CYP2D6
5 dopamine binding GO:0035240 9.37 DRD2 DRD3
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.32 DRD2 DRD3
7 superoxide dismutase activity GO:0004784 9.26 NQO1 SOD2
8 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD2 DRD3
9 oxygen binding GO:0019825 9.13 CYP1A2 CYP2D6 SOD2
10 drug binding GO:0008144 8.92 CYP2D6 DRD2 DRD3 HTR2A

Sources for Tardive Dyskinesia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....